ClinicalTrials.gg
RecruitingNCT03593317BRAVEUpdated Feb 9, 2026

Blockade of the Renin-angiotensin-aldosterone System in Patients With ARVD

A Phase 2 interventional study of Spironolactone and Placebo in Arrhythmogenic Right Ventricular Dysplasia, sponsored by Hospices Civils de Lyon. Recruiting at 13 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Hospices Civils de Lyon · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Arrhythmogenic right ventricular dysplasia (ARVD) is a rare cardiomyopathy characterized by the progressive replacement of cardiomyocytes by fatty and fibrous tissue in the right ventricle (RV). These infiltrations lead to cardiac electrical instability and ventricular arrhythmia.

Current treatment for ARVD is empirical and essentially based on treatment of arrhythmia. Thus, there is no validated treatment that will prevent the deterioration of the RV function in patients with ARVD.

The investigator's hypothesis is that the use of anti-fibrotic medications will prevent or at least reduce the deterioration of the RV function. The aim of this project is to evaluate the effect of spironolactone, a Potassium-sparing diuretic on ventricular myocardial remodeling and on arrhythmia burden in patients with ARVD.

The trial is a double-blind parallel multicenter prospective randomized phase II drug study. Patients will be randomized in the two groups: spironolactone or placebo. 13 centers in France will enroll the 120 patients (60 per group). Patients will be followed for 3 years (6 months, 1 year and 3 years) with all examinations (ECG, HA ECG, 24-hour Holter, trans-thoraciqc echocardiography (TTE), biological analyses) according to standard of care. A decrease in right and/or left ventricular deterioration and in arrhythmia burden are expected in ARVD patients treated with spironolactone. This reduction will improve the quality of life of patients and will reduce the number of hospitalizations and the risk of terminal heart failure.

02

Conditions studied

  • Arrhythmogenic Right Ventricular Dysplasia

Keywords

  • Heart Failure
  • Right ventricle
03

In context

Arrhythmogenic Right Ventricular Dysplasia

49 studies on the registry are indexed under Arrhythmogenic Right Ventricular Dysplasia; 29 are open to participants now.

This study's planned enrollment of 120 is above the median of 22 across 15 interventional studies indexed under Arrhythmogenic Right Ventricular Dysplasia.

Browse Arrhythmogenic Right Ventricular Dysplasia studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >18years old
  • Diagnosis of ARVD based on Task Force criteria. Two major criteria: 1 morphologic and one rhythmic or 1 major and 2 minor criteria established by the European Society of Cardiology/International Society and Federation of Cardiology.
  • >40%
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Patients under judicial protection.
  • Female patient who is pregnant or lactating, or is of child bearing potential (defined as a sexually mature woman not surgically sterilized or not for at least 24 consecutive months if ≤ 55 years or 12 months if > 55 years) and who did not agree to use highly effective methods of throughout the study.
  • No health insurance.
  • Right heart failure patient (RV volume>150ml).
  • Spironolactone : anuria, hyperkalemia (K+>5 mmol/l), renal failure (DFGCréat>22 mL/min/1,73 m2), end-stage liver failure, Addison's Disease, to spironolactone or to any of the (patients with galactose intolerance, lapp lactase deficiency or glucose or galactose malabsorption syndrome), association with eplerenone, association with other hyperkalemic diuretics, association with potassium salts, not recommended in cirrhotic patients (natraemia\<125 mmol/l) or in patients likely to present an acidosis.
  • Mandatory indication for a combination of ACE inhibitor and sartan or renin inhibitor (each authorized separately).
  • Acute phase of systemic disease.
  • Uncompensated hypothyroidism.
  • Acute hyperthyroidism.
  • Normal right ventricular volume.
  • Heart transplantation.
  • Swallowing disorders.
  • Participation in any other interventional clinical investigation that may have an impact on our study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Spironolactone group

    Drug: Spironolactone

  • Placebo comparator
    Placebo group

    Drug: Placebo

Interventions

  • The doses used in the study are the doses used in standard clinical practice. Initial dose is 25 mg/day until study end . The duration of treatment for each patient is 12 months.

  • DrugPlacebo

    Placebo will be taken once a day at the same time of day. The duration of treatment for each patient is 12 months.

06

What researchers measure

Primary outcomes

  1. Right ventricle longitudinal strain measured by echocardiography

    Time frame: at year 1

  2. Right ventricle infundibulum diameter measured by echocardiography

    Time frame: at year 1

  3. number of ventricular extrasystoles > 500 on 24h-Holter ECG

    Time frame: at year 1

Secondary outcomes

  1. number of ventricular extrasystoles on 24h-Holter ECG

    Time frame: at year 1

  2. number of palpitations

    Time frame: at year 1

  3. number of palpitations

    Time frame: at year 3

  4. number of ventricular tachycardia

    Time frame: at year 1

  5. number of ventricular tachycardia

    Time frame: at year 3

  6. number of dyspnea

    Time frame: at year 1

  7. number of dyspnea

    Time frame: at year 3

  8. number of syncope

    Time frame: at year 1

  9. number of syncope

    Time frame: at year 3

  10. number of sudden death

    Time frame: at year 1

  11. number of sudden death

    Time frame: at year 3

  12. number of thoracic pain

    Time frame: at year 1

  13. number of thoracic pain

    Time frame: at year 3

  14. number of MACE (Major adverse cardiac events)

    Time frame: at year 1

  15. number of MACE (Major adverse cardiac events)

    Time frame: at year 3

  16. number of hospital admissions

    Time frame: at year 1

  17. number of hospital admissions

    Time frame: at year 3

  18. left ventricle diameters measured by echocardiography

    Morphologic criterion

    Time frame: at year 1

  19. left ventricle diameters measured by echocardiography

    Morphologic criterion

    Time frame: at year 3

  20. left ventricle volumes measured by echocardiography

    Morphologic criterion

    Time frame: at year 1

  21. left ventricle volumes measured by echocardiography

    Morphologic criterion

    Time frame: at year 3

  22. left ventricle ejection fraction measured by echocardiography

    Morphologic criterion

    Time frame: at year 1

  23. left ventricle ejection fraction measured by echocardiography

    Morphologic criterion

    Time frame: at year 3

  24. Left ventricular global longitudinal strain measured by echocardiography

    Morphologic criterion

    Time frame: at year 1

  25. aneurism measured by echocardiography

    Morphologic criterion

    Time frame: at year 1

  26. aneurism measured by echocardiography

    Morphologic criterion

    Time frame: at year 3

  27. dyskinesia measured by echocardiography

    Morphologic criterion

    Time frame: at year 1

  28. dyskinesia measured by echocardiography

    Morphologic criterion

    Time frame: at year 3

  29. evolution of QRS width (50mm/s) on ECG

    Morphologic criterion

    Time frame: at year 1

  30. number of ventricular extrasystoles on 24h Holter ECG

    Rhythmic criterion

    Time frame: at year 1

  31. sustained ventricular tachycardia on 24h Holter ECG

    Rhythmic criterion

    Time frame: at year 1

  32. evolution of PR interval duration on ECG

    Rhythmic criterion

    Time frame: at year 1

  33. late potentials measured with high amplification ECG

    Rhythmic criterion

    Time frame: at year 3

  34. number of ventricular extrasystoles by stress test

    Rhythmic criterion

    Time frame: at year 3

  35. Evolution of functional symptoms by recording adverse events

    Functional criteria

    Time frame: at year 3

  36. Number of hospital admissions owing to clinical deterioration

    Time frame: at year 3

  37. Evolution of telediastolic right ventricle volume measured by echocardiography

    according to the genotype of desmosome genes

    Time frame: at year 3

  38. arrhythmia burden measured by 24h Holter ECG

    according to the genotype of desmosome genes

    Time frame: at year 3

  39. Dosage of MMP9 (Matrix metallopeptidase 9)

    Quantification of fibrosis

    Time frame: at year 1

  40. Dosage of MMP9 (Matrix metallopeptidase 9)

    Quantification of fibrosis

    Time frame: at year 3

  41. Dosage of TIMP1 (Tissue Inhibitory MetalloProtease 1)

    Quantification of fibrosis

    Time frame: at year 1

  42. Dosage of TIMP1 (Tissue Inhibitory MetalloProtease 1)

    Quantification of fibrosis

    Time frame: at year 3

  43. Dosage of TIMP2 (Tissue Inhibitory MetalloProtease 2)

    Quantification of fibrosis

    Time frame: at year 1

  44. Dosage of TIMP2 (Tissue Inhibitory MetalloProtease 2)

    Quantification of fibrosis

    Time frame: at year 3

  45. Dosage of IL6 (Interleukin 6)

    Quantification of inflammation

    Time frame: at year 1

  46. Dosage of IL6 (Interleukin 6)

    Quantification of inflammation

    Time frame: at year 3

  47. Dosage of IL8 (Interleukin 8)

    Quantification of inflammation

    Time frame: at year 1

  48. Dosage of IL8 (Interleukin 8)

    Quantification of inflammation

    Time frame: at year 3

07

Study locations

5 of 13 sites recruiting
08

References and documents

Publications

  • Alexandrino FB, Faaborg-Andersen CC, daSilva-deAbreu A. Anticoagulation in patients with atrial fibrillation and heart failure: More than meets the eye? Int J Cardiol. 2024 Feb 15;397:131591. doi: 10.1016/j.ijcard.2023.131591. Epub 2023 Nov 17. No abstract available. PubMed 37979797 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2027, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Jul 20, 2018
StartActual
Dec 20, 2024
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2029
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03593317
Responsible party
Sponsor
First posted
Jul 20, 2018
Start date
Dec 20, 2024
Primary completion
Dec 2027 (estimated)
Completion
Dec 2029 (estimated)
Last update
Feb 9, 2026

Study contacts

Roucher Aude, PhD
Contact
aude.roucher@chu-lyon.fr
426739447 ext. +33
Philippe Chevalier, MD, PhD
Contact
philippe.chevalier@chu-lyon.fr
4 72 35 70 27 ext. +33
Philippe Chevalier, MD, PhD
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Spironolactone

Start the discussion